ACUR - Acura Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.70
-0.02 (-2.78%)
As of 3:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.72
Open0.76
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.70 - 0.77
52 Week Range0.29 - 1.40
Volume20,103
Avg. Volume25,203
Market Cap14.557M
Beta2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301

    PALATINE, Ill., Jan. 08, 2018-- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 for ...

  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube25 days ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Acura Pharmaceuticals, Inc. – Elite Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Innoviva, Inc., Aradigm Corporation, OPKO Health, Inc., Pfizer Inc., Nektar Therapeutics, Windtree Therapeutics, Inc. and Pain Therapeutics, Inc. ... Read more (Read more...)

  • GlobeNewswire2 months ago

    Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results

    PALATINE, Ill., Nov. 13, 2017-- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September ...

  • Capital Cube4 months ago

    ETFs with exposure to Acura Pharmaceuticals, Inc. : September 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Acura Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACUR-US. Comparing the performance and risk of Acura Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
    Capital Cube4 months ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Acura Pharmaceuticals, Inc. – Elite Pharmaceuticals, Inc., OPKO Health, Inc., Innoviva, Inc., Rigel Pharmaceuticals, Inc., Pfizer Inc., Johnson & Johnson, Aradigm Corporation, Nektar Therapeutics and Pain Therapeutics, Inc. ... Read more (Read more...)

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ACUR earnings conference call or presentation 15-Aug-17 12:30pm GMT

    Q2 2017 Acura Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE5 months ago

    Investor Network: Acura Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 15, 2017 / Acura Pharmaceuticals, Inc. (NASDAQ: ACUR ) will be discussing their earnings results in their Q2 Earnings Call to be held August 15, 2017 at 8:30 AM Eastern ...

  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube8 months ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Acura Pharmaceuticals, Inc. – Windtree Therapeutics, Inc., Innoviva, Inc., Aradigm Corporation, Johnson & Johnson, OPKO Health, Inc., Pfizer Inc., Nektar Therapeutics, Rigel Pharmaceuticals, Inc. and Pain Therapeutics, Inc. ... Read more (Read more...)

  • Capital Cube9 months ago

    ETFs with exposure to Acura Pharmaceuticals, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Acura Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACUR-US. Comparing the performance and risk of Acura Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
    Capital Cube10 months ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 3.77 million, Net Earnings of USD 1.53 million. Gross margins widened from 96.19% to 96.23% compared to the same period last year, operating (EBITDA) margins now 48.21% from -23.33%. Change in operating ... Read more (Read more...)

  • Thomson Reuters StreetEvents10 months ago

    Edited Transcript of ACUR earnings conference call or presentation 3-Apr-17 12:30pm GMT

    Q4 2016 Acura Pharmaceuticals Inc Earnings Call